115 related articles for article (PubMed ID: 27461337)
1. Automated quantification of Ki67/MART1 stains may prevent false-negative melanoma diagnoses.
Wandler A; Spaun E; Steiniche T; Nielsen PS
J Cutan Pathol; 2016 Nov; 43(11):956-962. PubMed ID: 27461337
[TBL] [Abstract][Full Text] [Related]
2. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
3. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
4. Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Raundahl J; Steiniche T
Arch Pathol Lab Med; 2012 Jun; 136(6):627-34. PubMed ID: 22646269
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
6. Automated quantification of MART1-verified Ki-67 indices: useful diagnostic aid in melanocytic lesions.
Nielsen PS; Spaun E; Riber-Hansen R; Steiniche T
Hum Pathol; 2014 Jun; 45(6):1153-61. PubMed ID: 24704158
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
8. Observational Study Examining the Diagnostic Practice of Ki67 Staining for Melanocytic Lesions.
Vyas NS; Charifa A; Desman GT; Goldberg M; Singh R; Phelps RG; McNiff JM
Am J Dermatopathol; 2019 Jul; 41(7):488-491. PubMed ID: 31233404
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
10. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
11. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.
Schimming TT; Grabellus F; Roner M; Pechlivanis S; Sucker A; Bielefeld N; Moll I; Schadendorf D; Hillen U
Am J Dermatopathol; 2012 May; 34(3):266-9. PubMed ID: 22197861
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.
Nielsen PS; Riber-Hansen R; Steiniche T
Pathology; 2018 Jun; 50(4):402-410. PubMed ID: 29678478
[TBL] [Abstract][Full Text] [Related]
13. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
15. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.
Phadke PA; Rakheja D; Le LP; Selim MA; Kapur P; Davis A; Mihm MC; Hoang MP
Am J Surg Pathol; 2011 May; 35(5):656-69. PubMed ID: 21436676
[TBL] [Abstract][Full Text] [Related]
16. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
17. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.
Ikenberg K; Pfaltz M; Rakozy C; Kempf W
J Cutan Pathol; 2012 Mar; 39(3):324-30. PubMed ID: 22335591
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical double nuclear staining for cell-specific automated quantification of the proliferation index - A promising diagnostic aid for melanocytic lesions.
Brogård MB; Nielsen PS; Christensen KB; Georgsen JB; Wandler A; Lade-Keller J; Steiniche T
Pathol Res Pract; 2024 Mar; 255():155177. PubMed ID: 38330618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]